Dermatovate cream is a local glucocorticosteroid that is prescribed for various skin diseases. It induces the formation of lipocortin proteins that inhibit the activity of phospholipase A2, inhibits the formation of arachidonic acid and its metabolic products - prostaglandins, leukotrienes. Eliminates edema, hyperemia, itching at the site of application.
Dermatovate, when applied topically, is absorbed into systemic circulation. A more pronounced effect is manifested when applied to large areas of the skin. It is metabolized mainly in the liver, a small part - in the kidneys. It is excreted in the urine.
Dermatovate has the following actions:
Ointment is prescribed for the following diseases:
• lichen planus;
• discoid lupus erythematosus;
• dermatoses resistant to therapy with less active glucocorticosteroids for external use.
Do not use Dermatovate in the following cases:
• hypersensitivity to the main or auxiliary components of the drug.
• bacterial, viral and fungal skin diseases;
• rosacea (rosacea);
• skin cancer;
• hyde's knobby pruritus;
• perioral dermatitis;
• itchy skin in the absence of inflammation;
• perianal and genital itching;
• common plaque psoriasis;
• age up to 1 year;
• lactation period.
Dermatovate Cream may cause the following side effects:
• infection caused by opportunistic organisms.
• inhibition of the hypothalamic-pituitary-adrenal system. Signs of a cushingoid (moon-shaped face, central obesity), delayed weight gain and / or stunted growth in children, osteoporosis, glaucoma, hyperglycemia and / or glucosuria, cataracts, hypertension, weight gain or obesity, decreased endogenous cortisol, alopecia, brittle hair.
• itching, burning sensation, or soreness.
• local atrophy of the skin, striae, telangiectasia
• thinning, wrinkling of the skin, dry skin, changes in pigmentation, hypertrichosis, aggravation of the symptoms of the disease, allergic contact dermatitis, pustular psoriasis, erythema, rash, urticaria.
• general disorders and disorders at the injection site
• irritation and / or pain at the site of application. When applied to large surfaces for a long period of time (for example, more than 14 days), patients may develop systemic side effects: gastritis, ulceration of the mucous membrane of the gastrointestinal tract, increased intraocular pressure; symptoms of hypercorticism.
When used topically, the medication Dermatovate can be absorbed in quantities sufficient to cause the development of systemic effects. The development of acute overdose is unlikely. However, in case of chronic overdose or improper use of the medication Dermatovate, symptoms of hypercorticism may develop.
In case of an overdose, the medication should be gradually withdrawn, reducing the frequency of application or replacing it with a less active glucocorticosteroid, under the supervision of a doctor because of the risk of adrenal insufficiency.
It was shown that the simultaneous use of a medication capable of inhibiting the CYP3A4 isoenzyme (for example, ritonavir and itraconazole) inhibits the metabolism of glucocorticosteroids, leading to an increase in their systemic exposure. The degree of clinical significance of this interaction depends on the dose and method of administration of glucocorticosteroids and the activity of the inhibitor of the CYP3A4 isoenzyme.
The application of the cream is especially advisable on wet or wet surfaces.
The cream is applied with a thin layer in an amount not greater than that required to cover the entire affected area, one to two times a day, gently rubbed. Duration of use - until the effect or, if necessary, up to 4 weeks. Do not treat for more than 4 weeks. If prolonged treatment is necessary, the frequency of application should be gradually reduced or less active medications should be used. After each application of the medication Dermatovate, before applying the emollient, it is necessary to provide sufficient time for absorption.
To prevent exacerbations of skin diseases, short (intermittent) courses of the Dermatovate are carried out.
In especially resistant cases, especially in the presence of hyperkeratosis, the effect of the medication Dermatovate, cream for external use of 0.5 mg / g, if necessary, can be enhanced by applying an occlusive dressing (plastic film) overnight to the area of application of the medication, which is usually accompanied by positive dynamics of symptoms.In the future, the achieved effect can usually be maintained without the use of an occlusive dressing.
The maximum weekly dose should not exceed 50 g / week.
Dermatovate medication treatment should be gradually withdrawn immediately after disease control is achieved, and emollient treatment should be continued as maintenance therapy.
Sudden withdrawal of the medication Dermatovate can lead to a relapse of previously existing dermatoses.
Dermatoses characterized by a persistent course.
In the case of acute illness, as soon as the effect of a continuous course of treatment with glucocorticosteroid is achieved, the possibility of intermittent use (once a day, twice a week, without an occlusive dressing) can be considered. It is shown that such treatment effectively reduces the frequency of relapse.
The application of the medication should be continued on all previously affected areas of the skin or on known areas of potential exacerbation. This application should be combined with the routine daily use of emollients.
Use in children under the age of one year is contraindicated.
Children are more likely to develop local and systemic side effects during glucocorticosteroid therapy for external use and, as a rule, they require shorter courses of treatment using less active agents than adults. If possible, the duration of treatment in children should not exceed five days, the need for further use should be regularly assessed. In children, the medication should not be used under occlusive dressings.
Caution should be exercised when using the Dermatovate in children to ensure that it is applied in a minimum amount that provides a therapeutic effect.
Clinical studies have not revealed any differences in the effectiveness of the medication in elderly and younger patients. The high prevalence of decreased liver or kidney function in elderly patients can lead to a slowdown in the elimination of the medication in case of systemic absorption. Therefore, it should be used in elderly patients in a minimal amount and for the shortest possible period, but at the same time ensuring the achievement of the necessary clinical effect. Patients with impaired renal and / or liver function
In the case of systemic absorption of the medication (when applied to large surfaces of the skin over an extended period), its metabolism and excretion may slow down, leading to an increased risk of developing systemic toxicity. Therefore, it should be used in such patients in a minimal amount and for the shortest possible period, while ensuring the achievement of the necessary clinical effect.
Please consult your physician before taking any medication. Generic Name: CLOBETASOL - TOPICAL Pronounced: (kloh-BAY-tuh-sall) Temovate Top Uses: This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Clobetasol reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a very strong (super-high-potency) corticosteroid. Temovate may also be used for purposes other than those listed in this medication guide.